Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Urothelial Carcinoma
Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:
Bladder cancer is common in the UK and can kill. A common sign of bladder cancer is blood in the urine (haematuria). GPs will refer to a specialist (Urologist) for further investigation of haematuria if they suspect cancer.
- Trial name
- IDENTIFY (NCT03548688)
- Where
- United Kingdom
- Volunteers
- 11,059 people
- Sponsor
- British Urology Researchers in Surgical Training
Bladder Cancer
Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy drugs directly into the bladder may kill more cancer cells.
- Trial name
- NCT00042887
- Testing
- mitomycin C, conventional surgery
- Where
- 12 sites in Belgium, Italy and 3 more
- Volunteers
- 58 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
RESECT: Improving Quality in TURBT Surgery.
Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC), is the most common type of bladder cancer. It is expensive to manage and significantly impacts on patients' quality of life.
- Trial name
- RESECT (NCT05154084)
- Testing
- Performance feedback and education
- Where
- United Kingdom
- Volunteers
- 19,505 people
- Sponsor
- British Urology Researchers in Surgical Training
Bladder Cancer
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Primary Objective: 1. To compare the proportion of patients free from progression 9 months from the start of consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel alone.
- Trial name
- NCT00479089
- Testing
- Docetaxel, ZD1839, Dexamethasone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Urinary Bladder Cancer, Urinary Bladder Neoplasm
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to…
- Conditions
- Urinary Bladder Cancer, Urinary Bladder Neoplasm, BCG, Trans Urethral Resection of a Bladder Tumor
- Trial name
- NCT05946369
- Testing
- Neutrophil to lymphocyte ratio
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Ain Shams University
Bladder Cancer Recurrence, Intravesical Instillation
Intraoperative vs. Postoperative Intravesical Epirubicin Instillation for Prevention of Bladder Recurrence in High-Risk Upper Urinary Tract Urothelial Carcinoma
Upper urinary tract urothelial carcinoma (UTUC) accounts for 5%-10% of urothelial malignancies, with up to 50% of patients developing bladder recurrence post-RNU.
- Conditions
- Bladder Cancer Recurrence, Intravesical Instillation, Upper Urinary Tract Carcinoma
- Trial name
- IEPBR (NCT06941038)
- Where
- Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Ankara Etlik City Hospital
Melanoma, Solid Tumor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions…
- Conditions
- Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification
- Trial name
- NCT04985604
- Testing
- Tovorafenib
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Hematuria, Urothelial Neoplasm
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.
- Conditions
- Hematuria, Urothelial Neoplasm, Urothelial Carcinoma, Bladder Cancer
- Trial name
- SeARCH (NCT06026189)
- Testing
- urine-first strategy
- Where
- Netherlands
- Volunteers
- 1,100 people
- Sponsor
- Erasmus Medical Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network